Market Overview:

The global anti-obesity therapeutics market in terms of revenue was estimated to be worth USD 6,931.21 Million in 2023 and is poised to reach 89,719.49 Million by 2032, growing at a CAGR of 32.9% from 2024 to 2032.

The anti-obesity therapeutics market refers to a segment specifically focused on discovering and promoting treatments that fight against the condition known as obesity; this is a highly complex health condition characterized by an excessive accumulation of body fats. This condition has nowadays become a pandemic character with much public health concern due to its association with various comorbidities such as type 2 diabetes, cardiovascular diseases, hypertension, and numerous cancers. With the trend of obesity incidence increasing alarmingly in the world, there is an urgent need for effective anti-obesity interventions and, in this regard, escalating research efforts and investments.

The market contains several treatment modalities, primarily pharmacotherapy, but also surgical interventions, behavioural therapies, and medical devices. Pharmacotherapy constitutes the most important component of this therapeutic arsenal, representing prescription medications intended to reduce weight through the mechanisms of inducing appetite suppression, increasing sensations of fullness, or modifying metabolic operations. The three currently available classes of drugs in the market are stimulants, serotonin receptor agonists, GLP-1 receptor agonists, and fat-absorption inhibitors. Therefore, with the recent approvals by regulatory authorities, for example the U.S. Food and Drug Administration of new anti-obesity drugs there has been an increase in the availability of anti-obesity therapies.

The largest market for anti-obesity therapeutics is in North America, driven by a high prevalence of obesity, heavy health care expenditures, and the presence of the world's top pharmaceutical companies. However, the Asia-Pacific region will grow at the fastest rates due to the increasing prevalence of obesity and the changing lifestyle factors associated with rising awareness of the risks obesity poses to health. This increasing awareness is being translated into more aggressive approaches to weight management through the enhancement of pharmacotherapy combined with lifestyle interventions.

High treatment costs are significant factors impacting the anti-obesity therapeutics market; additionally, there have been side effects due to drugs and inconsistent reimbursement policies in different regions. Moreover, in the most instances, pharmacotherapy is still the best solution when combined with behavioural modifications and changes in lifestyles, thus it needs an holistic approach to weight management.

The future of anti-obesity therapeutics appears bright, especially since further technological and scientific advances will continue to reveal more effective treatments. As such, the market is likely to shift towards increasingly innovative and effective therapeutic solutions tailored towards this critical global health problem - obesity.

Key Findings

• In November 2023 Lilly announced the approval of Zepbound by the USFDA for managing chronic weight in adults with obesity
• In October 2022 Lilly received Fast Track Designation from USFDA for tirzepatide. The product is being studied for the treatment of obesity, or overweight in adults

Market Drivers

Rising Obesity Prevalence

Drivers behind the anti-obesity therapeutics market are the significantly increasing global obesity rates. Poor dietary choices, increased consumption of processed foods and above all, sedentary lifestyles have resulted in a tremendous increase in overweight and obese cases. Proportionately, more people are found obese as individuals become more sedentary and seek ease of life rather than nutritional value, which escalates as a public health concern.

This increasing trend has raised awareness of health risks associated with obesity, among other conditions, type 2 diabetes, cardiovascular diseases, and some cancers, making both the individual and care professionals question the effectiveness of weight loss solutions. Thus, a growing demand for pharmacological interventions to help loss of weight which reduces both short-term and long-term morbidity.

Responding to the demand, the market creates innovative anti-obesity medications by giving a robust landscape for research and investment purposes and providing effective therapies against the obesity epidemic and its associated health complications.

Key Findings

• In 2022, about 16% of adults aged 18 years and older worldwide were obese

Market Opportunities

Development of Novel Therapies

There is great hope for innovative medicines against several biological pathways involved in increasing appetite, metabolic pathways, and fat storage in the market of anti-obesity therapeutics. The aim of most anti-obesity treatments was for only a few years because most of the treatments depended on one mechanism; however, recent investigations focus on several pathways, which might be crucial to improve the treatment outcome and conditions of patients. The complex biological factors causing obesity shall determine new drug targets useful for effective weight management.

Also growing interest in combination therapy, that is the use of several drugs and/or treatment therapies administered together to enhance the effect of therapy. This method can be both for different mechanisms of action by counteractive thought mechanisms, such as reducing hunger and simultaneously increasing energy expenditure.

Personalized treatment also has great promise since it can be ideally tailored to the profiles of patients in relation to their genetic and metabolic as well as lifestyle factors. Personalization may, therefore, increase adherence and possibly effectiveness, which can translate into successful long-term weight management strategies for a number of patient populations.

Market Restraining Factors

Side Effects and Safety Concerns

Many anti-obesity drugs are associated with the potential side effects which, in turn, may greatly influence both patients' and providers' attitudes toward their administration. The potential side effects might range from very slight conditions, including nausea and diarrhoea, to more severe conditions which involve cardiovascular issues and psychological impacts, including anxiety and depression. These side effects enhance fears of safety problems for the patients, and they therefore do not opt for the pharmacological treatment of obesity.

Healthcare providers may be reluctant to prescribe these drugs because they fear litigation and patient harm. The perceived risk of these anti-obesity drugs motivates prescribing practices of the rather apprehensive healthcare providers, reducing access to effective treatment for weight management.

Side effect fear could make the patients seek alternatives, which may be lifestyle modification or non-pharmaceutical interventions. This could finally hamper the growth of the anti-obesity therapeutics market. Education for patients and providers about safety and management of side effects is vital for increasing acceptance and usage of these drugs.

Segmentation Analysis

The market scope is segmented because of by Drug Class, by Mechanism of Action, by Route of Administration, by Patient Type, by End-User, by Distribution Channel.

By Drug Class

Based on the Drug Class of the market is segmented into Prescription Medications, Over-the-Counter (OTC) Medications.

Prescription medications, notably semaglutide, garner most market shares due to their high efficacy and clinical evidence. The demand for safe and reliable weight loss treatments with high efficacy is considered an opportunity driving the anti-obesity therapeutics market. Prescription medications have been categorized into five subcategories: orlistat, phentermine-topiramate, bupropion-naltrexone, and GLP-1 receptor agonists, also referred to as semaglutide, among others, which are FDA-approved prescription drugs that require a healthcare provider's prescription. These drugs, especially for people with BMI above a certain threshold, prove to be effective in managing weight management. Among these, GLP-1 receptor agonists, particularly semaglutide, have been the opted drugs that have captured all the limelight as they effectively promote the loss of weight, currently dominating the prescription segment. OTC drugs, including less potent orlistat, sold over the counter provide a gateway to needy people who want easy access to some kind of weight loss solution. Lastly, dietary supplements, ranging from herbal products to nutraceuticals, are available again but less strictly tested than prescription drugs

By Mechanism of Action

Based on the  Mechanism of Action of the market is segmented into Appetite Suppressants, Fat Absorption Inhibitors, Metabolic Enhancers, Combination Therapies.

The anti-obesity drugs therapeutics market provides various classes of drugs that are well designed to address weight management issues, including appetite suppressants, fat absorption inhibitors, metabolic enhancers, and combination therapies. Appetite suppressants like phentermine are effective at reducing hunger signals, leading to increased rates of satiety and adherence to dietary restrictions. Fat absorption inhibitors, such as orlistat, are involved in the inhibition of the enzyme whose function is to digest the fat. Therefore, it causes the fats not to be absorbed from food, hence leading to weight loss. Metabolic enhancers, in this case bupropion increases metabolic rates and exerts energy upon expediting its efforts in providing assistance in managing weight.

Therapies have utilised various mechanisms to intensify the weight loss effect. For instance, in the prescription medication phentermine-topiramate - it combines two mechanisms: suppression of appetite joined together with increased energy expenditure as a more efficient and effective strategy in losing weight. This dual function makes the combination therapies stand out in the market that can offer an all-rounded benefit to create considerable weight loss in patients battling obesity.

Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America, particularly the United States, dominates the anti-obesity therapeutics market due to the high prevalence of obesity and a well-established healthcare system. The percentage of adults qualifying as obese in the population is noted to be at a high level with that not being treated, hence demanding weight management solutions to be effective. There is also an excellent pipeline for prescription drugs that involves representatives like semaglutide GLP-1 receptor agonists, which hold much promise in clinical trials. Increasing consciousness over risks associated with obesity such as diabetes and cardiovascular diseases fuels anti-obesity drug usage.

Europe is yet another important region where the rates of obesity are raising day by day, which indirectly boosts the demand for weight loss. Awareness programs undertaken by various nations across the world such as the United Kingdom, Germany, and France have enabled this fight to be brought closer to the people and thus, with the rising awareness, more and more people who harbour an interest in the disease and to treat it opt for therapeutic drugs. The regulatory environment is positive with the approval of EMA to many anti-obesity drugs. However, the market for these drugs is fragmented in Europe, as there is a great deal of variation in healthcare policies across nations that leave behind its effect on the accessibility and affordability of those drugs.

The Asia-Pacific region is fast-emerging as the biggest growth market for anti-obesity therapeutics. All of the people's swift pace of urbanization, sedentary lifestyle, and fast-changing dietary patterns contribute to a rising rate of obesity, mainly in populous countries like China and India. The increased rate of lifestyle diseases translates into an increasing demand for weight management solutions. Government initiatives and rising expenditure on health care also appear to be two key factors influencing access to anti-obesity drugs. But cultural attitudes to body weight and health will drive the level of treatment taken up by various countries.

Latin America is experiencing increasing cases of obesity, particularly in cities. Countries such as Brazil and Mexico have seen increasing demand for anti-obesity drugs due to greater awareness of the risks obesity poses. The market consists of prescription drugs and dietary supplements, with access to these still not reaching all areas due to affordability.

This represents a developing market for anti-obesity therapeutics in the Middle East and Africa. However, in contrast to the increasing prevalence of obesity, the growth challenges posed by health infrastructure and limited access to drugs can slow down market growth. However, a growing awareness of obesity-related health issues, coupled with the rising middle class, is projected to create new opportunities for therapeutic interventions in this region.

The anti-obesity therapeutics market is characterized by diverse regional dynamics where North America and Europe lead the market size, but Asia-Pacific has enormous growth potential. The heightened awareness of health risks associated with obesity worldwide will likely increase demand for effective weight management solutions, a factor driving the future of the market in all regions.

List of Companies Profiled

• Bristol-Myers Squibb
• Eisai Company
• GlaxoSmithKline plc
• Novo Nordisk
• Alizyme
• Boehringer Ingelheim GmbH
• Pfizer
• Takeda Pharmaceutical
• Rhythm Pharmaceuticals
• Shionogi USA
• Vivus

Key Industry Developments

• February 2022: Pfizer Inc. said the experiment on the oral diabetes drug glucagon-like peptide-1 receptors indicated that the drug can control type 2 diabetes and that obesity, commonly associated with type 2 diabetes, causes a decrease in patients' weight.
• November 2021: Novo Nordisk announced that the European regulatory authority, Committee for Medicinal Products for Human Use (CHMP), has adopted a positive opinion and has recommended marketing authorization for Wegovy for chronic weight management in adults with obesity.
• October 2021: Navamedic ASA further extended the distribution rights for Mysimba in the Nordics. Navamedic ASA acquired the exclusive distribution rights of Mysimba for the Nordics from Currax Pharmaceutical LLC formerly Orexigen Therapeutics Inc for five years in 2017.
• April 2021: Zealand Pharma A/S and Boehringer Ingelheim initiated Phase 2 trials of the GLP-1/glucagon dual agonist BI 456906 in overweight or obese adults and in NASH adults.

Report Coverage

The report will cover the qualitative and quantitative data on the Global Anti-Obesity Therapeutics Market. The qualitative data includes latest trends, market player’s analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Regional Analysis

North America accounted for the highest Anti Obesity Therapeutics Market % market share in terms of revenue in the Anti Obesity Therapeutics Market market and is expected to expand at a CAGR of Anti Obesity Therapeutics Market % during the forecast period. This growth can be attributed to the growing adoption of Anti Obesity Therapeutics Market . The market in APAC is expected to witness significant growth and is expected to register a CAGR of Anti Obesity Therapeutics Market % over upcoming years, because of the presence of key Anti Obesity Therapeutics Market companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Anti Obesity Therapeutics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Anti Obesity Therapeutics Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S.
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions

• How much the global Anti Obesity Therapeutics Market valued?
• Which region has the largest share in 2024 for the global Anti Obesity Therapeutics Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of the Market

• Historic year: 2019- 2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million

Anti Obesity Therapeutics Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: